Recombinant TNFRSF10B (Drozitumab Biosimilar) anticorps

N° du produit ABIN7795105

Cet anticorps anti-TNFRSF10B (Drozitumab Biosimilar) Monoclonal Souris (ABIN7795105) détecte spécifiquement TNFRSF10B (Drozitumab Biosimilar) dans FACS et in vivo. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour Recombinant TNFRSF10B (Drozitumab Biosimilar) anticorps (ABIN7795105)

Antigène: TNFRSF10B (Drozitumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TNFRSF10B (Drozitumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-TNFRSF10B (Drozitumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Drozitumab Biosimilar, TRAIL Monoclonal Antibody

Attributs du produit: Drozitumab Biosimilar uses the same protein sequences as the therapeutic antibody drozitumab. Drozitumab is a human monoclonal antibody in development for the treatment of cancers. It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells. Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human TRAIL

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur TNFRSF10B (Drozitumab Biosimilar)

Antigène: TNFRSF10B (Drozitumab Biosimilar)

Autre désignation: Drozitumab Biosimilar

Classe de substances: Biosimilar